RxDoctor Payments Data

Pankil Desai, MD

Interventional Cardiology · Indianapolis, INNPI 1518311984

Payments from drug & device makers

$8,762in general payments, 2019–2025

Across 164 payments — averaging $53.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$1K
  • Abbott$1K
  • Philips North America LLC$1K
  • Abiomed$704
  • AstraZeneca$584
  • plus $2K from 13 others

What the payments were for

  • Travel & lodging$2,06024%
  • Food & beverage$6,06269%
  • Education$6407%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,762 in reported general payments places this provider in the 50th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$77,180
Medicare patients
276
Services billed
766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$90,185
EntrestoSacubitril/Valsartan26$25,649
Repatha SureclickEvolocumab26$25,445
BrilintaTicagrelor29$22,477
JardianceEmpagliflozin26$17,829
VascepaIcosapent Ethyl33$15,640
Icosapent Ethyl23$2,158
Metoprolol Succinate156$2,020
Atorvastatin Calcium308$1,940
ClopidogrelClopidogrel Bisulfate181$1,720
Ranolazine ErRanolazine13$1,619
Amlodipine Besylate173$903
Ezetimibe44$796
Carvedilol137$751
Rosuvastatin Calcium77$689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$127$90,18585 claims
AstraZenecaBrilinta$584$22,47729 claims
Boehringer IngelheimJardiance$125$17,82926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →